CRYSTAL LUBIS: Open Payments
NPI 1174190409 · GERMANTOWN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,858 in 74 payments from 19 companies in 2025. Trend: 2023 $1,288 · 2024 $1,550 · 2025 $1,858
Food & beverage: $1,848Education: $10
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 11 | $323 |
| Ardelyx, Inc. | 11 | $307 |
| Janssen Biotech, Inc. | 9 | $264 |
| Madrigal Pharmaceuticals | 7 | $197 |
| GENZYME CORPORATION | 4 | $117 |
| Lilly USA, LLC | 7 | $110 |
| Celltrion USA Inc. | 3 | $84 |
| QOL Medical, LLC | 3 | $83 |
| ABBVIE INC. | 4 | $79 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $49 |
Products named: IBSRELA, Wegovy, TREMFYA, REZDIFFRA, DUPIXENT, ZEPBOUND, VEGZELMA, Sucraid.
Industry payments across MD — which companies pay providers there.
